Avid Bioservices Inc (CDMO)

[freethemice]

From today's online issue of the NCI Cancer Bulletin.
I think Peregrine should move ahead on breast cancer as soon as possible.
http://www.cancer.gov/ncicancerbulletin/072412/page12#c

Also in the Journals: No Overall Survival Benefit from Bevacizumab in Breast Cancer, Meta-Analysis Shows

A meta-analysis has shown that adding bevacizumab (Avastin) to chemotherapy may prolong progression-free survival in women with metastatic breast cancer, but the drug has no significant effect on overall survival or quality of life. The findings were published July 11 in the Cochrane Database of Systematic Reviews.
Researchers analyzed data from seven randomized trials involving more than 4,000 women with metastatic breast cancer. In the trials, treatment-related deaths were lower in women receiving bevacizumab, even though the drug increases the risk of serious adverse events that can lead to death.
“Because of the lack of effect on overall survival and quality of life,” the researchers concluded, “it is…controversial whether bevacizumab is associated with a true patient benefit [despite] the increase in progression-free survival.”